Zobrazeno 1 - 6
of 6
pro vyhledávání: '"Saori Matsuoka-Aizawa"'
Autor:
Satoshi Kimura, Shinichi Oka, Saori Matsuoka-Aizawa, Hiroyuki Gatanaga, Takao Takahashi, Hikaru Yamanaka, Pope Kosalaraksa
Publikováno v:
The Journal of infectious diseases. 195(10)
Mitochondrial toxicity is a major adverse effect of the nucleoside reverse-transcriptase inhibitors (NRTIs) used for treatment of human immunodeficiency virus type 1 (HIV-1) infection and can result in life-threatening lactic acidosis. The toxicity i
Autor:
Hironori Sato, Saori Matsuoka-Aizawa, Kazuhiko Koike, Shinichi Oka, Hiroyuki Gatanaga, Satoshi Kimura
Publikováno v:
Antiviral research. 70(2)
We previously described a clinical human immunodeficiency virus type-1 (HIV-1) isolate, CL-4, which showed nelfinavir (NFV)-dependent enhancement of replication (Matsuoka-Aizawa, S., Sato, H., Hachiya, A., Tsuchiya, K., Takebe, Y., Gatanaga, H., Kimu
Autor:
Saori Matsuoka-Aizawa, Shinichi Oka, Satoshi Kimura, Xiuqiong Bi, Hiroyuki Gatanaga, Kiyoto Tsuchiya, Setsuko Ida
Publikováno v:
Journal of acquired immune deficiency syndromes (1999). 34(1)
HIV-1 genotype assay using plasma viruses has been widely applied for detection of resistant viruses in infected individuals, whereas there are only a few reports about proviral genotype in peripheral blood mononuclear cells (PBMCs). To determine whi
Autor:
Shinichi Oka, Ikumi Genka, Katsuji Teruya, Kiyoto Tsuchiya, Akira Yasuoka, Yoshimi Kikuchi, Natsuo Tachikawa, Saori Matsuoka-Aizawa, Satoshi Kimura
Publikováno v:
Journal of clinical virology : the official publication of the Pan American Society for Clinical Virology. 27(3)
Nelfinavir (NFV) is a widely prescribed HIV-1 specific protease inhibitor (PI). However, there are only a few reports that have described the long-term effects of NFV-containing regimens, especially with regard to the emergence of drug resistance in
Autor:
Shinichi Oka, Masashi Tatsumi, Atsuko Hachiya, Satoshi Kimura, Kiyoto Tsuchiya, Hiroyuki Gatanaga, Saori Matsuoka-Aizawa
Publikováno v:
Journal of virological methods. 111(1)
A novel phenotypic anti-human immunodeficiency virus type 1 (HIV-1) drug resistance assay is described. Three drugs at concentrations equivalent to those determined in in vivo pharmacokinetics, were mixed in a well, serially diluted by 10-folds, and
Autor:
Yutaka Takebe, Atsuko Hachiya, Hiroyuki Gatanaga, Hironori Sato, Shinichi Oka, Kiyoto Tsuchiya, Satoshi Kimura, Saori Matsuoka-Aizawa
During the use of a phenotypic anti-human immunodeficiency virus type 1 (HIV-1) drug resistance assay in a large set of clinical virus isolates, we found a unique variant (CL-4) that exhibited a high level of nelfinavir (NFV) resistance and rather en
Externí odkaz:
https://explore.openaire.eu/search/publication?articleId=doi_dedup___::d8e0b5e4128f64e55428f47fcd806f43
https://europepmc.org/articles/PMC140576/
https://europepmc.org/articles/PMC140576/